局部noncorticosteroid免疫调节治疗特应性皮炎。

文章的细节

引用

复制到剪贴板

Reitamo年代,Remitz, Kyllonen H, Saarikko J

局部noncorticosteroid免疫调节治疗特应性皮炎。

是中国新药杂志。2002;3 (6):381 - 8。

PubMed ID

12113647 (在PubMed

]

文摘

目前,一线药物治疗特应性皮炎局部皮质激素治疗。他们是短期使用时有效;然而,长期使用糖皮质激素与抑制影响结缔组织、皮肤萎缩或抵抗治疗。目前,两个局部noncorticosteroid免疫调制剂他克莫司(吸收FK506)和pimecrolimus(981年SDZ ASM)正在发展,或在市场上已经在一些国家过敏性皮肤炎。这两个化合物结构相似。在T淋巴细胞它们绑定到相同的细胞受体,FK-binding蛋白(FKBP)或macrophilin-12。他克莫司显示FKBP而pimecrolimus三倍大的亲和力。他克莫司/ pimecrolimus-FKBP复杂的进一步结合钙调磷酸酶酶至关重要的早期激活T细胞。钙调磷酸酶绑定的结果缺乏辅助T细胞的激活类型1和2。进一步的影响已经提出这些化合物在其他炎症细胞,如朗格汉斯细胞和肥大细胞和嗜碱粒细胞。 In contrast to corticosteroids, no suppressive effects on connective tissue cells have been observed. Taken together, treatment of inflammation results in healing of the barrier function of the skin. This again results in reduced bioavailability of the drug, as compared with systemic use. Placebo-controlled studies have shown the efficacy of both tacrolimus (at 0.03 and 0.1%) and pimecrolimus (at 0.6 and 1%). The main adverse event in these studies has been a burning sensation and increased pruritus at the site of application. Typically, these adverse events are observed only during the first days of treatment. Long-term safety studies, of up to one year, have not revealed any new adverse events. So far, long-term use of topical noncorticosteroid compounds has not been associated with signs of immune deficiency. Although there is currently no evidence for clinically relevant, prolonged adverse effects, some of these, such as an increased risk of photocarcinogenesis, need to be monitored. There is evidence from tacrolimus studies that monotherapy results in better long-term results when compared with combination therapy with corticosteroids. Tacrolimus and pimecrolimus could replace topical corticosteroids as the first-line treatment of atopic dermatitis.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Pimecrolimus	Peptidyl-prolyl顺反异构酶FKBP1A	蛋白质	人类	未知的	电位器	细节
Pimecrolimus	丝氨酸/ threonine-protein激酶mTOR	蛋白质	人类	是的	电位器	细节